Abstract
Dupilumab, a monoclonal antibody targeting interleukin‐4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.

This publication has 14 references indexed in Scilit: